Investor Sues Biotech Capricor After Product's FDA Denial
By Emilie Ruscoe · July 18, 2025, 7:42 PM EDT
Biotechnology company Capricor Therapeutics Inc. faces a proposed investor class action alleging it misrepresented its lead product candidate's approval prospects before the U.S. Food and Drug Administration....
To view the full article, register now.